A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9

2006 ◽  
Vol 80 (4) ◽  
pp. 346-355 ◽  
Author(s):  
L THAM ◽  
B GOH ◽  
A NAFZIGER ◽  
J GUO ◽  
L WANG ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Single Nucleotide Polymorphisms ◽  
Vitamin K ◽  
Nucleotide Polymorphisms ◽  
Cytochrome P450 2C9 ◽  
Single Nucleotide ◽  
Vitamin K Epoxide Reductase ◽  
Epoxide Reductase ◽  
Warfarin Dosing

scholarly journals Rapid Single-Nucleotide Polymorphism Detection of Cytochrome P450 (CYP2C9) and Vitamin K Epoxide Reductase (VKORC1) Genes for the Warfarin Dose Adjustment by the SMart-Amplification Process Version 2

2009 ◽  
Vol 55 (4) ◽  
pp. 804-812 ◽  
Author(s):  
Tohru Aomori ◽  
Koujirou Yamamoto ◽  
Atsuko Oguchi-Katayama ◽  
Yuki Kawai ◽  
Takefumi Ishidao ◽  
...  
Keyword(s):  
Single Nucleotide Polymorphism ◽  
Cytochrome P450 ◽  
Vitamin K ◽  
Maintenance Dose ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide ◽  
Vitamin K Epoxide Reductase ◽  
Epoxide Reductase ◽  
Amplification Process

Abstract Background: Polymorphisms of the CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) gene (CYP2C9*2, CYP2C9*3) and the VKORC1 (vitamin K epoxide reductase complex, subunit 1) gene (−1639G>A) greatly impact the maintenance dose for the drug warfarin. Prescreening patients for their genotypes before prescribing the drug facilitates a faster individualized determination of the proper maintenance dose, minimizing the risk for adverse reaction and reoccurrence of thromboembolic episodes. With current methodologies, therapy can be delayed by several hours to 1 day if genotyping is to determine the loading dose. A simpler and more rapid genotyping method is required. Methods: We developed a single-nucleotide polymorphism (SNP)-detection assay based on the SMart Amplification Process version 2 (SMAP 2) to analyze CYP2C9*2, CYP2C9*3, and VKORC1 −1639G>A polymorphisms. Blood from consenting participants was used directly in a closed-tube real-time assay without DNA purification to obtain results within 1 h after blood collection. Results: We analyzed 125 blood samples by both SMAP 2 and PCR-RFLP methods. The results showed perfect concordance. Conclusions: The results validate the accuracy of the SMAP 2 for determination of SNPs critical to personalized warfarin therapy. SMAP 2 offers speed, simplicity of sample preparation, the convenience of isothermal amplification, and assay-design flexibility, which are significant advantages over conventional genotyping technologies. In this example and other clinical scenarios in which genetic testing is required for immediate and better-informed therapeutic decisions, SMAP 2–based diagnostics have key advantages.

scholarly journals Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9

Biochemistry ◽  
2017 ◽  
Vol 56 (41) ◽  
pp. 5476-5480 ◽  
Author(s):  
Keiko Maekawa ◽  
Motoyasu Adachi ◽  
Yumiko Matsuzawa ◽  
Qinghai Zhang ◽  
Ryota Kuroki ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Single Nucleotide Polymorphisms ◽  
Structural Basis ◽  
Nucleotide Polymorphisms ◽  
Cytochrome P450 2C9 ◽  
Single Nucleotide

Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients

2007 ◽  
Vol 120 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Rina Kimura ◽  
Kotaro Miyashita ◽  
Yoshihiro Kokubo ◽  
Yasuhisa Akaiwa ◽  
Ryoichi Otsubo ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Vitamin K ◽  
Warfarin Dose ◽  
Japanese Patients ◽  
Cytochrome P450 2C9 ◽  
Vitamin K Epoxide Reductase ◽  
Epoxide Reductase
Sign in / Sign up

Export Citation Format

Share Document